7V3.F Cantargia AB (publ)
- Market cap
- EUR 28.0M
- P/E
- 1.4x
- P/B
- 1.22x
- ROE
- -49.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7V3.F undervalued?
Graham numberThe Graham number of Cantargia AB (publ) cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cantargia AB (publ) fundamental analysis
No fundamental analysis for Cantargia AB (publ) yet.
Cantargia AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inf…
Full company profileCantargia AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cantargia AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 317M | 1.21M |
| Operating Income | -44.7M | -59.8M | -92.8M | -111M | -173M | -368M | -380M | -288M | -168M | 154M | -145M |
| EBITDA | - | -60.3M | -91.2M | -111M | -170M | -363M | -368M | -277M | -158M | 154M | -114M |
| Net Income | -44.7M | -60.3M | -91.2M | -111M | -173M | -367M | -372M | -280M | -162M | 147M | -132M |
| EPS | - | -1.28 | -1.38 | -1.52 | -1.73 | -3.66 | -2.23 | -1.52 | -0.88 | 0.59 | -0.47 |
| Balance Sheet | |||||||||||
| Total Assets | 47.5M | 274M | 171M | 166M | 926M | 600M | 475M | 224M | 170M | 297M | 308M |
| Total Liabilities | 10.4M | 28.3M | 16.4M | 23.8M | 33.6M | 67.5M | 85.1M | 55.0M | 54.1M | 30.8M | 43.9M |
| Shareholders' Equity | 37.1M | 246M | 155M | 142M | 892M | 533M | 390M | 169M | 116M | 266M | 264M |
| Cash & Short-term Investments | 25.9M | 150M | 76.5M | 39.9M | 693M | 247M | 190M | 140M | 33.0M | 282M | 210M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -42.3M | -40.8M | -105M | -111M | -156M | -346M | -359M | -292M | -163M | 150M | -127M |
| Capital Expenditure | 2.81M | 6.88M | 6.88M | 6.88M | 890K | 383K | 7.09M | 0.00 | 0.00 | 472K | 94.0K |
| Free Cash Flow | - | -41.1M | -105M | -118M | -165M | -347M | -366M | -299M | -163M | 150M | -127M |
| Ratios | |||||||||||
| ROE | -120.3% | -24.5% | -58.8% | -77.9% | -19.4% | -68.8% | -95.4% | -165.9% | -139.0% | 55.3% | -49.9% |
| ROA | -94.0% | -22.0% | -53.2% | -66.7% | -18.7% | -61.1% | -78.3% | -125.2% | -94.9% | 49.5% | -42.8% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | 46.4% | -10,910.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cantargia AB (publ) dividends
Cantargia AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Cantargia AB (publ)
- Insiders 9.47%
- Institutions 26.79%
- Public & others 63.74%
- Shares outstanding 282M
- Free float 238M
Cantargia AB (publ) company profile
- Company name
- Cantargia AB (publ)
- Ticker
- 7V3.F
- ISIN
- SE0006371126
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- Ideon Gateway, Lund, Sweden, 223 63
- Phone
- 46 4 62 75 62 60
- Website
- cantargia.com
About Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Cantargia AB (publ) management
10- Dr. Hilde Hermansen Steineger M.Sc., MSc, Ph.D.Chief Executive Officer · born 1966
- Mr. Thoas Fioretos M.D., Ph.D.Founder & Scientific Advisor · born 1962
- Mr. Marcus JäråsFounder & Scientific Advisor
- Mr. Kjell SjöströmFounder
- Mr. Patrik RenbladChief Financial Officer · born 1970
- Dr. David LibergChief Scientific Officer · born 1969
- Ms. Nina ValkamaExecutive Assistant of Administration & Finance
- Mr. Antonius BerkienChief Business Officer · born 1968
- Dr. Monic Stuart M.B.A., M.D., Ph.D.Chief Medical Officer
- Johanna ChristensenFinancial Controller